The Scale of the Problem
For patients: read the sections on personal economic impact (lost income, costs) to understand the financial dimension of the illness.
For caregivers: read the caregiver-burden and cost sections to understand the economic strain on families.
For clinicians: read the economic-impact sections to understand the broader burden of the disease on patients and society.
For researchers: read the Scale of the Problem and Evidence Gaps and Research Directions sections to inform health-economic research.
ME/CFS imposes economic costs that are systematically underestimated, because the disease itself is systematically underdiagnosed. An estimated 84β91% of U.S. patients remain undiagnosed (Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2015) β every cost estimate in this chapter is therefore a lower bound, capturing only the visible fraction of the diseaseβs economic footprint.
The 2015 Institute of Medicine report established the baseline: 836,000 to 2.5 million Americans affected, with annual economic costs of USD 17β24 billion, including USD 9.1 billion in lost household and labor-force productivity (Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2015). This represented USD 18,000β29,000 per patient per year, with indirect costs (lost earnings, reduced work hours, informal care) accounting for approximately two-thirds of the total. The IOM estimate remains the most widely cited single number for U.S. ME/CFS economic burden, though it is a modeled extrapolation from prevalence surveys and cost data, not a direct measurement from claims or administrative databases. (Certainty: 0.77 β government report by National Academies; modeled estimate, not direct cost measurement; extrapolated from survey data. IOM + Clayton 2015 summary share the same evidence base β treated as one source.)
Consequence: The USD 17β24 billion figure β even treated as a lower bound β places ME/CFS in the same economic tier as well-recognized chronic diseases. For a policymaker deciding where to allocate research funding, this number should trigger the same institutional response as the economic burden of multiple sclerosis or rheumatoid arthritis. It has not. Severity applicability: the cost estimate does not stratify by severity; indirect costs are likely underestimated for severe/very severe patients whose caregivers face the highest economic burden.
Australian cost-of-illness studies independently confirm the IOM magnitude and extend it with direct patient-level measurement. Zhao et al. (2023) estimated AU$14.5 billion in total annual costs (AU$28,800 per patient), with indirect costs dominating β lost productivity, informal care, and reduced workforce participation (Zhao et al. 2023). Close et al. (2020), using a separate Australian cohort (n=485), found mean annual costs of AU$14,523 per patient, with 73% attributable to indirect costs and only 16.6% of patients employed (Close et al. 2020). The convergence of two independent Australian studies β different samples, different years, different methodologies β with the IOM U.S. estimate suggests the economic burden is not a methodological artefact of any single study. (Certainty: 0.70 β two independent cost-of-illness studies with convergent estimates; both cross-sectional; n=128 + n=485; Australian data, not U.S. claims-based.)
Consequence: Cross-national replication of the cost magnitude strengthens the case that ME/CFS is inherently expensive β not expensive because of any countryβs specific healthcare or disability system. The diseaseβs cost structure (indirect costs >> direct costs) is consistent across countries, consistent with a disease that removes people from the workforce at high rates and provides them with few effective medical treatments. Severity applicability: neither Australian study stratified costs by severity; the 16.6% employment rate may not generalize to mild patients who continue working part-time.
The KCE Belgian ME/CFS needs assessment (Cornelis et al. 2026, n=749 survey + 19 qualitative interviews) provides the most recent population-level economic data from a government HTA agency. Mean duration of work invalidity: 8.6 years. 73.2% of patients had at least one comorbidity. Diagnostic delay exceeded 2 years for 50% of patients (Cornelis et al. 2026b) (Cornelis et al. 2026a). The KCE report is significant not for any single number but because a government health technology assessment body β whose output typically informs reimbursement and care-pathway decisions β conducted a formal needs assessment for ME/CFS, implicitly recognizing it as a condition warranting systematic health-economic evaluation. (Certainty: 0.68 β government HTA report; survey + qualitative; Belgium-specific; cross-sectional.)
Consequence: When a government HTA agency formally evaluates ME/CFS, it signals institutional recognition that the disease is a legitimate object of health-economic analysis. The 8.6-year mean work invalidity duration translates directly to lost tax revenue, increased disability payments, and reduced household economic security β consequences that accrue to the state, not just the patient. Severity applicability: KCE weighted toward moderate/severe patients (survey methodology); mild patients underrepresented; very severe patients β who cannot complete surveys β entirely absent.